Can a vaccine stop ovarian cancer from resisting treatment?
NCT ID NCT05479045
First seen Mar 22, 2026 · Last updated Jun 23, 2026 · Updated 15 times
Summary
This phase 2 trial tests whether adding a cancer vaccine (NY-ESO-1) to an immunotherapy drug (toripalimab) can prevent resistance in women with stage III or IV ovarian cancer that no longer responds to platinum chemotherapy. The study plans to enroll 24 participants and will measure how long the cancer stays controlled. It is not yet recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER STAGE IV are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
John Theurer Cancer Center
Hackensack, New Jersey, 07601, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, 20007, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NY-ESO-1 peptide vaccine combined with toripalimab (an immunotherapy drug)
What this could lead to
If successful, this combination could help control advanced ovarian cancer by preventing resistance to standard immunotherapy, potentially extending life.
What could go wrong
This is a small, early-phase trial with only 24 participants, so results may not apply broadly. The vaccine and drug combination may cause side effects or fail to improve outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.